NCCN临床实践指南_膀胱癌(2019.V4)英文版

Version 4 2019 07 10 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Bladder Cancer Version 4 2019 July 10 2019 Continue NCCN org For important information regarding the BCG shortage see MS 11 Also see the AUA BCG Shortage Notice NCCN Guidelines Version 4 2019 Bladder Cancer Version 4 2019 07 10 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion NCCN Guidelines Panel Disclosures Continue Hematology Hematology oncology Internal medicine Medical oncology Pathology Radiotherapy Radiation oncology Surgery Surgical Oncology Urology Discussion writing committee member Thomas W Flaig MD Chair University of Colorado Cancer Center Philippe E Spiess MD MS Vice Chair Moffitt Cancer Center Neeraj Agarwal MD Huntsman Cancer Institute at the University of Utah Rick Bangs MBA Patient Advocate Stephen A Boorjian MD Mayo Clinic Cancer Center Mark K Buyyounouski MD MS Stanford Cancer Institute Sam Chang MD MBA Vanderbilt Ingram Cancer Center Tracy M Downs MD University of Wisconsin Carbone Cancer Center Jason A Efstathiou MD DPhil Massachusetts General Hospital Cancer Center Terence Friedlander MD UCSF Helen Diller Family Comprehensive Cancer Center Richard E Greenberg MD Fox Chase Cancer Center Khurshid A Guru MD Roswell Park Comprehensive Cancer Center Harry W Herr MD Memorial Sloan Kettering Cancer Center Christopher Hoimes MD Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Brant A Inman MD MSc Duke Cancer Institute Masahito Jimbo MD PhD MPH University of Michigan Rogel Cancer Center A Karim Kader MD PhD UC San Diego Moores Cancer Center Subodh M Lele MD Fred cT4a N0 cT1 cT4a N1 Primary and Adjuvant Treatment BL 6 Stage IIIB cT1 cT4a N2 3 Primary and Subsequent Treatment BL 7 Stage IVA cT4b Any N M0 Any T Any N M1a Primary and Subsequent Treatment BL 8 Metastatic Disease Additional Workup Primary Treatment BL 9 Follow up Recurrent or Persistent Disease BL 10 Principles of Imaging for Bladder Urothelial Cancer BL A Principles of Surgical Management BL B Principles of Pathology Management BL C Bladder Cancer Non Urothelial and Urothelial with Variant Histology BL D Follow up BL E Principles of Intravesical Treatment BL F Principles of Systemic Therapy BL G Principles of Radiation Management of Invasive Disease BL H Upper GU Tract Tumors Renal Pelvis UTT 1 Urothelial Carcinoma of the Ureter UTT 2 Urothelial Carcinoma of the Prostate UCP 1 Primary Carcinoma of the Urethra PCU 1 Staging ST 1 Clinical Trials NCCN believes that the best management for any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged To find clinical trials online at NCCN Member Institutions click here nccn org clinical trials clinicians aspx NCCN Categories of Evidence and Consensus All recommendations are category 2A unless otherwise indicated See NCCN Categories of Evidence and Consensus NCCN Categories of Preference All recommendations are considered appropriate See NCCN Categories of Preference The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment The National Comprehensive Cancer Network NCCN makes no representations or warranties of any kind regarding their content use or application and disclaims any responsibility for their application or use in any way The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network All rights reserved The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN 2019 Printed by Maria Chen on 7 10 2019 11 54 03 PM For personal use only Not approved for distribution Copyright 2019 National Comprehensive Cancer Network Inc All Rights Reserved NCCN Guidelines Version 4 2019 Bladder Cancer Version 4 2019 07 10 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion UPDATES Updates in Version 1 2019 of the NCCN Guidelines for Bladder Cancer from Version 4 2018 include Bladder Cancer INTRO This is a new page BL 1 Primary Evaluation Surgical Treatment Preferred added to gemcitabine Footnote c was updated Immediate intravesical chemotherapy reduces the recurrenc